Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 2017; DOI: 10.1056/NEJMoa1707914
Inflammatory hypothesis confirmed: Landmark randomized clinical trial of high-risk patients finds that a drug targeting inflammation reduced risk of major adverse cardiovascular events. Investigators from Brigham and Women’s Hospital today announced results of a clinical trial culminating from 25 years of cardiovascular research work. Paul M...
Read More
Recent Comments